Leah Kuntz

Badr Ratnakaran, MBBS, Psychiatric Times' new Climate Change Section Editor, explores the intersection of climate change and mental health, highlighting the urgent need for awareness and support in clinical practice.

Brigitte Robertson, MD, shares information on innovative, genetically targeted treatments for alcohol use disorder, aiming to personalize care and improve patient outcomes.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Stay informed with this week's highlights, including more on dementia prevention, a treatment for alcohol use disorder, National Nurses Week, and finding joy.

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

Stay informed with this week's highlights, including more on deep brain stimulation, innovative assessments for borderline personality disorder, and athlete mental health research.

NRx Pharmaceuticals secures FDA fee waiver for NRX-100, a preservative-free ketamine aimed at treating suicidal depression, enhancing accessibility for patients.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Explore the evolving role of psychotherapy in psychiatry in our May theme! We want to hear about your insights, tips, and case studies.

Check out the pipeline updates from April!

2025: a big year for emergency psychiatry. Don't miss any of our Special Report articles!

A groundbreaking study explores innovative neuroassessment technology to enhance understanding and treatment of borderline personality disorder symptoms.

Stay informed with this week's highlights in psychiatric advancements, including emergency psychiatry, a major update on Cobenfy, new partnerships for better treatments, and more.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

Explore key updates in psychiatric health, including Black maternal health, self-harm insights, schizophrenia treatment advancements, and expert interviews.

About 40% of women who have postpartum depression go unrecognized and untreated, and they are still symptomatic 3 years later.

Does trontinemab represent the next generation of anti-amyloid monoclonal antibodies thanks to Brainshuttle technology? New research looks encouraging.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

Do you want to be featured in a future Special Report? Check out our April theme!

What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.

The FOCUS phase 3 trial of solriamfetol for the treatment of ADHD demonstrated statistically significant improvements in ADHD symptoms and disease severity.

Check out new data from the long-term, open-label KINECT 4 study on Ingrezza capsules for the treatment of tardive dyskinesia.

Alzamend announced a late 2025 initiation for the phase 2 clinical study of AL001, a novel lithium-delivery system for the treatment of patients with major depressive disorder.

March 17 through March 23 is National Drug and Alcohol Facts Week 2025.